FOLH1 and chronic kidney disease: Schäfer et al. [31] presented three cases of mCRPC, treated with high-activity (54.8 to 69.5 GBq) [177Lu] Lu-PSMA-I&T RLT, resulting in significant renal toxicity (CTCAE grade 3–4 chronic kidney disease, CKD).